Trial Profile
Profiling and Reversing Metabolic Insufficiency in the Tumor Microenvironment in Advanced Melanoma: A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 17 Apr 2023
Price :
$35
*
At a glance
- Drugs Metformin (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 13 Apr 2023 Planned End Date changed from 1 Dec 2028 to 1 Dec 2027.
- 13 Apr 2023 Planned primary completion date changed from 1 Jan 2027 to 1 Jan 2026.
- 05 Jan 2018 Status changed from not yet recruiting to recruiting.